Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Purine nucleoside phosphorylase gene therapy - GeoVax Labs/PNP Therapeutics

Next Previous
Drug Profile

Purine nucleoside phosphorylase gene therapy - GeoVax Labs/PNP Therapeutics

Alternative Names: Ad/PNP; Ad/PNP/F-araAMP; Adenovirus/PNP; Gedeptin

Latest Information Update: 03 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Southern Research Institute; University of Alabama
  • Developer PNP Therapeutics
  • Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pharyngeal neoplasms; Orofacial cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Squamous cell cancer
  • Phase Unknown Pharyngeal neoplasms

Most Recent Events

  • 31 Dec 2024 GeoVax Labs completes a phase I/II trial in Squamous cell cancer (Late-stage disease, Metastatic-disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural) (NCT03754933)
  • 22 Jan 2024 GeoVax Labs completes enrolment in a phase I/II trial in Squamous cell cancer (Late-stage disease, Metastatic-disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural) before January 2024 (NCT03754933) (GeoVax Labs pipeline, January 2024)
  • 10 Jul 2023 Adverse events and efficacy data from a phase I/II trial in Squamous cell cancer released by GeoVax Labs

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top